Ultragenyx Pharmaceutical - Stock Price History | RARE

Historical daily share price chart and data for Ultragenyx Pharmaceutical since 2021 adjusted for splits. The latest closing stock price for Ultragenyx Pharmaceutical as of September 27, 2021 is 88.66.
  • The all-time high Ultragenyx Pharmaceutical stock closing price was 177.39 on December 23, 2020.
  • The Ultragenyx Pharmaceutical 52-week high stock price is 179.65, which is 102.6% above the current share price.
  • The Ultragenyx Pharmaceutical 52-week low stock price is 76.78, which is 13.4% below the current share price.
  • The average Ultragenyx Pharmaceutical stock price for the last 52 weeks is 112.25.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Ultragenyx Pharmaceutical Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 80.1825 43.1100 177.3900 33.8000 138.4300 224.12%
2019 54.0178 41.7200 74.3600 36.0800 42.7100 -1.77%
2018 62.8406 49.2900 90.1500 38.8900 43.4800 -6.25%
2017 61.1255 69.9700 88.8000 43.5400 46.3800 -34.03%
2016 66.2144 101.8600 101.8600 47.2600 70.3100 -37.32%
2015 87.3311 46.4000 134.0900 46.4000 112.1800 155.65%
2014 46.7982 42.2500 66.1800 33.3600 43.8800 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.014B $0.271B
Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29